Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age.

Tosin Omole¹, Enrique Pelayo², Aaron S Weinberg³, Spyros Chalkias⁴, Zelalem Endale⁴, Gretchen Tamms¹, Tina M Sterling¹, Lori Good¹, Tulin Shekar¹, Morgan Johnson¹, Natalie Banniettis¹, Ulrike K Buchwald¹, Alejandra Esteves-Jaramillo¹

¹Merck & Co., Inc., Rahway, NJ 07065, USA.

²Advanced Medical Research Institute, Miami, FL 33174, USA.

³Carbon Health, North Hollywood, CA 91606, USA.

⁴Moderna, Cambridge, MA 02142, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND/OBJECTIVES: Streptococcus pneumoniae with, or following, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with increased mortality, particularly in older adults. However, vaccination can be an effective preventative measure. This Phase 3 study (NCT05158140) assessed the immunogenicity and safety of co-administering the SARS-CoV-2 vaccine mRNA-12…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.